SWOG Network Group Operations Center of the NCTN

SWOG网络运营拨款申请中的影响报表简明扼要地总结了我们的工作 我们的目标是：通过不断提高包容性、参与度和科学创新， SWOG将加强癌症临床试验的开发和进行，减轻人类的负担 肿瘤。 SWOG国家临床试验网络集团已将自己确立为一个创新、协作、 一种性价比高的NCTN成分。SWOG拥有60年的审判经验，其工作导致了 美国食品和药物管理局批准14种方案，改变和通报肿瘤学实践 成百上千次。在2013年的拨款申请中，我们承诺为 新的NCTN企业，我们在过去五年中成功地做到了这一点。我们坚定地致力于 在接下来的六年里进一步努力。SWOG设计和指导高价值、途径和免疫- 推动肿瘤学研究，目标是实现对双方都有意义的改变实践的结果 受癌症影响的人和调查人员。该组织目前的网络包括1000多个 会员网站，有5000名医生在美国、加拿大、韩国、墨西哥、 沙特阿拉伯和南美。23个NCI指定的癌症中心在我们的 成员，以及肿瘤学研究卓越的22个专门项目。从2014年初到 2017年年中，SWOG调查人员发表了188多篇癌症治疗文章和摘要，以及 纳入12,819名患者参加NCTN治疗试验。SWOG在NCTN Direct方面积极协作 研究和行政职能，并开发了培训和教育工具 网络。 SWOG的使命是通过癌症临床试验和翻译来显著改善生活 研究。以下指导原则于2017年9月批准，是我们建立在以下基础上的基础 实现这一目标： -我们把病人放在绝对最优先的位置 -我们确保最好的科学推动我们的研究 -我们欢迎和鼓励领导层和成员的多样性，以有效解决问题 在癌症中 -我们要求SWOG的诚信、责任感和道德行为 -我们培养和指导年轻的研究人员，以确保为子孙后代进行优秀的临床研究 在下一个赠款周期中，我们将提供一个高效、创新和灵活的网络，能够 开发和实施国外的临床和转化性试验框架；我们将 为NCTN做出有意义的贡献；我们将帮助患者过上更长、更有意义的生活。SWOG 在下一代肿瘤疗法的设计中仍将是一股创新力量。

The impact statement in SWOG's network operations grant application succinctly summarizes our work and our goals: By continuously improving inclusion, engagement, and scientific innovation, SWOG will enhance cancer clinical trial development and conduct, reducing the burden of human neoplasm. The SWOG National Clinical Trials Network Group has established itself as an innovative, collaborative, a n d cost-effective NCTN constituent. SWOG has 60 years of trial experience, and its work has led to the Food and Drug Administration approval of 14 regimens, changing and informing oncologic practice hundreds of time more. In our 2013 grant application, we promised to make unique contributions to the new NCTN enterprise, and we successfully did so over the last five years. We are strongly committed to furthering our efforts over the next six. SWOG designs and directs high-value, pathway- and immune- driven oncology research, with the goal of achieving practice-changing results that are meaningful to both persons affected by cancer and investigators. The group's current network includes more than 1,000 member sites, with 5,000 physicians who practice across the United States, Canada, South Korea, Mexico, Saudi Arabia, and South America. Twenty-three NCI-designated cancer centers number among our members, as do 22 Specialized Programs in Oncology Research Excellence. From early 2014 through mid-2017, SWOG investigators published more than 188 cancer treatment articles and abstracts, and enrolled 12,819 patients into NCTN therapeutic trials. SWOG actively collaborates in NCTN direct research and administrative functions and has developed training and education tools used throughout the network. SWOG's mission is to significantly improve lives through cancer clinical trials and translational research. The following guiding principles, ratified in 9/2017, are the foundation upon which we build to achieve that end: — We make patients our absolute highest priority — We ensure that the best science drives our research — We embrace and encourage diversity in leadership and membership, to effectively solve problems in cancer — We demand integrity, accountability, and ethical behavior in SWOG — We foster and mentor young investigators, to ensure excellent clinical research for future generations Over the next grant cycle, we will provide an efficient, innovative, and nimble network capable of developing and conducting abroad framework of clinical and translational trials; we will meaningfully contribute to the NCTN; and we will help patients lead longer and meaningful lives. SWOG will remain an innovative force in the design of the next generation of oncologic therapies.